drug_type
RELEVANT_DRUG
intervention_type
biologic peptide vaccine
drug_description
Synthetic long peptide (26 aa) vaccine derived from CMV pp65, formulated in Montanide ISA 51 to induce CMV-specific CD8+ cytotoxic T cells, CD4+ helper T cells, and antibody responses via MHC class I/II; adjuvant enhances dendritic cell activation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Cytomegalovirus Vaccines
drug_category
PEPTIDE VACCINE
drug_class
Vaccine
drug_delivery_route
Intradermal
drug_mechanism_of_action
Synthetic long peptide from CMV pp65 formulated in Montanide ISA 51; after injection, peptides are taken up by dendritic cells and presented on MHC class I/II to prime and expand CMV‑specific CD8+ cytotoxic T cells, CD4+ helper T cells, and antibody responses. The Montanide adjuvant provides a depot and enhances dendritic-cell activation, promoting immunity against CMV-expressing tumor cells.
drug_name
PEP-CMV
nct_id_drug_ref
NCT05096481